Atopic Dermatitis

The AJMC® Atopic Dermatitis compendium is a comprehensive resource for clinical news and expert insights for the chronic skin condition that typically develops in early childhood.

Latest News

Atopic Dermatitis | Image Credit: © slobodyan_78-stock.adobe.com
Biomarker Insights Differentiate JAK1 vs IL-13 Therapy in AD

September 10th 2025

AD-related outcomes were compared in patients treated with JAK1 inhibitors and IL-13 antibodies, with short-term efficacy biomarkers considered for treatment outcomes.

Atopic dermatitis | Image Credit: © VectorMine-stock.adobe.com.
Key Risk Factors Uncovered for AD Recurrence After Dupilumab Discontinuation

September 5th 2025

Dermatitis word cloud | Image Credit: © Words Collage Cloud-stock.adobe.com
Atopic Dermatitis Skin Clearance Maintained Over 3 Years With Lebrikizumab

August 28th 2025

Atopic dermatitis on hands | Image Credit: © Ольга Тернавская - stock.adobe.com
Yearly Flares in Atopic Dermatitis May Predict Disease Severity

August 20th 2025

Roflumilast cream | Image Credit: © luchschenF-stock.adobe.com
Roflumilast Cream 0.05% Durable, Safe for Younger Pediatric Patients

August 15th 2025

Topical Therapies for the Treatment of Atopic Dermatitis: Balancing Safety, Efficacy, and Access

Develop a deeper understanding of the atopic dermatitis (AD) patient journey, explore topical therapies and treatment sequencing advancements, and gain insight regarding the payer’s perspective on AD therapies.

Atopic Dermatitis Payer Perspectives

More News

Robert Sidbury, MD, MPH.
March 17th 2022

Dr Robert Sidbury Addresses Quality-of-Life Burden in Atopic Dermatitis

Matthew Gavidia
Along with common symptoms of itch and pain, patients with atopic dermatitis experience significant work productivity and attention issues that affect overall quality of life, said Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital.
Person clenching hand.
March 15th 2022

Upadacitinib Shows Sustained Efficacy, Safety in Moderate to Severe Atopic Dermatitis

Matthew Gavidia
Longer-term findings of the Measure Up 1 and 2 studies showed the JAK inhibitor upadacitinib to be safe and effective after 52 weeks in the treatment of adults and adolescents with moderate to severe atopic dermatitis.
Robert Sidbury, MD, MPH.
March 13th 2022

Dr Robert Sidbury on Psychosocial, Behavioral Issues Linked With Atopic Dermatitis

Matthew Gavidia
Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital, discussed the psychosocial and behavioral issues faced by patients with atopic dermatitis, particularly those with severe disease.
Study Examines Dupilumab's Effect on EoE When Given for AD, Other Conditions
March 11th 2022

Study Examines Dupilumab's Effect on EoE When Given for AD, Other Conditions

Allison Inserro
Administering dupilumab for other atopic conditions, including atopic dermatitis (AD) and asthma, in patients who also have eosinophilic esophagitis (EoE), resulted in improved EoE symptoms.
Person with itchy skin.
March 9th 2022

Skin Barrier Function in Moderate to Severe AD Significantly Improved With Dupilumab

Matthew Gavidia
Dupilumab was shown to significantly improve factors of skin barrier function, including transepidermal water loss, lipid composition, and filaggrin, among patients with moderate to severe atopic dermatitis.
Nurse and patient.
March 4th 2022

Multidisciplinary Approach Identifies Allergic, Immunology Burden in Severe AD

Matthew Gavidia
Patients with severe atopic dermatitis showed significant associations with concomitant contact dermatitis and immune dysfunction after undergoing a multidisciplinary evaluation between allergy, immunology, and dermatology specialists.
Child.
March 1st 2022

Significant Disease Burden Found in Children With Moderate to Severe AD

Matthew Gavidia
Uncontrolled disease burden was a major unmet need among children with moderate to severe atopic dermatitis (AD) who were unresponsive to topical therapies.
Depression.
February 25th 2022

Worse Health-Related QOL, Mental Health in Patients With AD During the Pandemic

Matthew Gavidia
Polish patients with atopic dermatitis reported lower overall health and impaired quality of life related to mental health in the first year of the COVID-19 pandemic.
Robert Sidbury, MD, MPH.
February 24th 2022

Dr Robert Sidbury Discusses Utilization, Efficacy of Biologics for Atopic Dermatitis

Matthew Gavidia
Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital, speaks on the efficacy of biologics in the treatment of atopic dermatitis and other recently approved therapeutics.
Robert Sidbury, MD, MPH.
February 18th 2022

Dr Robert Sidbury on Risk Factors, Diagnosis of Atopic Dermatitis

Matthew Gavidia
Robert Sidbury, MD, MPH, chief of the Division of Dermatology at Seattle Children's Hospital, discusses risk factors involved in the pathogenesis of atopic dermatitis and several diagnostic methods.
Rural land.
February 17th 2022

Jobs in Forestry, Agriculture Linked With Increased AD Risk in Workers' Children

Matthew Gavidia
Japanese children of parents whose family business was primarily industry, including agriculture, forestry, and fisheries, had a greater risk of atopic dermatitis (AD) development.
Child.
February 12th 2022

AD Severity Linked With Sleep, Attention Issues in Young Children

Matthew Gavidia
Children with moderate to severe atopic dermatitis were found to be more likely to report suboptimal sleep and attention regulation outcomes.
Robert Sidbury, MD, MPH.
February 11th 2022

Dr Robert Sidbury Explains Pathophysiology, Comorbidity Risk of Atopic Dermatitis

Matthew Gavidia
Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital, speaks on the inflammatory mechanisms of atopic dermatitis and risk of comorbidities in affected patients.
FDA
February 3rd 2022

FDA Approves Abrocitinib for Adults With Moderate to Severe Atopic Dermatitis

Matthew Gavidia
The JAK1 inhibitor abrocitinib (Cibinqo) was recently approved by the FDA for the treatment of adults with refractory, moderate to severe atopic dermatitis.
Stethoscope.
January 31st 2022

Social Determinants May Influence Health Care Utilization, Symptom Burden in Patients With Asthma and Eczema

Matthew Gavidia
Minority patients and those with low income were more likely than White and high-income counterparts to report adverse outcomes in the management of asthma and eczema.
Flare.
January 29th 2022

Understanding, Managing Flares in Atopic Dermatitis

Matthew Gavidia
Researchers review current knowledge on the management of flares in atopic dermatitis, including treatment and unmet needs.
Health cross symbol.
January 27th 2022

Dupilumab Significantly Reduces Hospitalization Rates in Patients With Atopic Dermatitis

Matthew Gavidia
Patients with atopic dermatitis (AD) treated with dupilumab showed reduced hospitalization rates and shorter duration of AD-related hospitalizations vs those treated with control therapies.
Health care cost.
January 21st 2022

Substantial Cost Burden, Health Care Utilization Found in Patients With Severe Atopic Dermatitis

Matthew Gavidia
Patients with atopic dermatitis were associated with significant economic burden primarily driven by outpatient visits and pharmacy use, which increased with disease severity.
Physician, parent, and sick child.
January 19th 2022

Early-Life Infection Linked With Atopic Dermatitis Development in Infants, Children

Matthew Gavidia
Incidence of infectious diseases, skin infections, and systemic antibiotic exposure were all associated with the development of atopic dermatitis among infants and young children.
Spotlighting a patient.
January 13th 2022

Greater Risk of COVID-19 Infection Found in Patients With Atopic Dermatitis

Matthew Gavidia
Patients with atopic dermatitis were shown to be more likely to receive a COVID-19 diagnosis than the general population.
Child with mask.
January 11th 2022

Atopic Dermatitis Associated With Behavioral Issues in Children and Adolescents

Matthew Gavidia
Children and adolescents with atopic dermatitis (AD) tended to have a higher number of delinquent behaviors than those without AD, including fighting, cheating on exams, and suspension.
Person grasping hand.
January 6th 2022

Real-World Study Finds Dupilumab Safe, Effective for Moderate-to-Severe Atopic Dermatitis

Matthew Gavidia
Korean patients with moderate-to-severe atopic dermatitis achieved and maintained markedly improved skin clearance with dupilumab treatment in a real-world setting, including in the face and hands.
David R. Stukus, MD, FACAAI.
December 28th 2021

Dr David R. Stukus Spotlights Unmet Needs in Atopic Dermatitis Management

David R. Stukus, MD, FACAAI, of Nationwide Children's Hospital and The Ohio State University College of Medicine, and a board member of the American College of Allergy, Asthma & Immunology, speaks on the lack of interventions to manage the underlying causes of exacerbation in atopic dermatitis.
Nurse and medical provider.
December 24th 2021

Evaluating Differences in Therapeutic, Diagnostic Approaches to Atopic Dermatitis

Matthew Gavidia
A study found significant differences in the therapeutic and diagnostic approaches to atopic dermatitis used by allergists, dermatologists, and pediatricians, and those recommended by guidelines.
David R. Stukus, MD, FACAAI.
December 22nd 2021

Dr David R. Stukus Discusses Access, Affordability Concerns of Emerging Atopic Dermatitis Therapies

David R. Stukus, MD, FACAAI, of Nationwide Children's Hospital and The Ohio State University College of Medicine, and a board member of the American College of Allergy, Asthma & Immunology, speaks on the difficulties of gaining coverage for newer biologic therapies in the treatment of atopic dermatitis.
Happy child.
December 18th 2021

Dupilumab Shows High Effectiveness in AD for Ages 6 Months and Up

Matthew Gavidia
Research presented at the Revolutionizing Atopic Dermatitis (RAD) Virtual Conference said dupilumab (Dupixent) is an effective and safe therapeutic option in adults, adolescents aged 6 to 11 years, and young children aged 6 months to 5 years with moderate-to-severe atopic dermatitis.
David R. Stukus, MD, FACAAI.
December 17th 2021

Dr David R. Stukus on Immune-Related Response to Therapy in Atopic Dermatitis

David R. Stukus, MD, FACAAI, of Nationwide Children's Hospital and The Ohio State University College of Medicine, and a board member of the American College of Allergy, Asthma & Immunology, discusses efforts to align novel treatments for atopic dermatitis with patients based on the underlying mechanisms of disease.
Many Questions Remain in Deciphering, Preventing Atopic March
December 14th 2021

Many Questions Remain in Deciphering, Preventing Atopic March

Jared Kaltwasser
In a new review article, investigators outline the challenges to studying the disease, but also point to big data as an important tool moving forward.
Person closing eye.
December 9th 2021

Patients With Atopic Dermatitis More Prone to Depression, Anxiety

Matthew Gavidia
Patients with atopic dermatitis, particularly those with more severe skin manifestations, were shown to be at greater risk of depression and anxiety compared with the general population.
Child in a hospital bed.
December 7th 2021

Increased Risk of Fracture Found in Children With Atopic Dermatitis

Matthew Gavidia
Children with atopic dermatitis were shown to be at an increased risk of fractures compared with the general population, with systemic use of corticosteroid and antihistamine therapy cited as mediating factors.
<1
...
3456789>

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo